Actinium Pharma

ACTINIUM PHARMACEUTICALS INC

Actinium Pharmaceuticals

Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications, and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.

movers image

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

AGRI

ATNM

ATPC

BJDX

CHGG

CNSP

HPAI

LCID

LUMN

PLTR

RXST

SERV

SMFG

SPWR

TENK

TPET

UPXI

Why Palantir Technologies Shares Are Trading Higher By Around 10%; Here Are 20 Stocks Moving Premarket

wall street ai9

Earnings

Eurozone

Commodities

Intraday Update

VBIV

S&amp;P 500 Down Over 100 Points; Actinium Pharmaceuticals Shares Plunge

Miscellaneous Services

Dow Tumbles 950 Points; ISM Services PMI Surges In July

Actinium Pharmaceuticals, Inc. (Delaware) Common Stock

Actinium Pharmaceuticals Inc

Press Releases

ATNM INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Actinium Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Legal

ROSEN, A LONGSTANDING LAW FIRM, Encourages Actinium Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ATNM

ATNM Investors Have Opportunity to Lead Actinium Pharmaceuticals, Inc. Securities Fraud Lawsuit

Actinium Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before May 27, 2025 to Discuss Your Rights - ATNM

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of May 27, 2025 in Actinium Lawsuit – ATNM

DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Actinium

ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Actinium Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ATNM

Shareholders that lost money on Actinium Pharmaceuticals, Inc.(ATNM) should contact The Gross Law Firm about pending Class Action - ATNM

Actinium Pharmaceuticals, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky Before May 27, 2025 to Discuss Your Rights – ATNM

ATNM Stockholders Should Contact Robbins LLP for Information on How to Lead the Class Action Against Actinium Pharmaceuticals, Inc.

Agenus

Armata Pharmaceuticals, Inc. Common Stock

Armata Pharmaceuticals

Burning Rock Biotech Limited - American Depositary Shares

Burning Rock Biotech

Cue Biopharma

Dyadic International, Inc. - Common Stock

Dyadic International

Fortress Biotech

Forte Biosciences

Gain Therapeutics

Immix Biopharma

Century Therapeutics, Inc. - Common Stock

Century Therapeutics

LakeShore Biopharma Co., Ltd - Ordinary Shares

LakeShore Biopharma

MAIA Biotechnology

Mersana Therapeutics, Inc. - Common Stock

Mersana Therapeutics

OnKure Therapeutics, Inc. - Class A Common Stock

OnKure Therapeutics

OKYO Pharma

OSR Holdings

Outlook Therapeutics, Inc. - Common Stock

Outlook Therapeutics

PDS Biotechnology Corporation - Common Stock

PDS Biotechnology

Prelude Therapeutics Incorporated - Common Stock

Prelude Therapeutics

Rein Therapeutics

Repare Therapeutics

Skye Bioscience

Sutro Biopharma

vTv Therapeutics Inc. - Class A Common Stock

vTv Therapeutics

X4 Pharmaceuticals

HC Wainwright & Co.

Stephens & Co.

Maxim Group

Cantor Fitzgerald

B. Riley Securities

Screenshot 2024-02-29 at 7.16.11 PM

Biotech

General

COEP

Here&#39;s How Coeptis Therapeutics Is Innovating Cell Therapy Approaches

Comments

Actinium Pharma

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga